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In medicine, cost-of-illness studies play a role as they might 
be used as references for resource allocation, development of 
policy, and for determination of the cost-effectiveness of new 
therapies.1 Chronic hepatitis C (CHC) is a serious worldwide 
health-related burden, and recent development and introduction 
of direct-acting antivirals (DAAs) for CHC has made a substan-
tial push toward looking the disease from the economic point 
of view.2 Economic impact of CHC and its management can 
be evaluated by two different approaches. The first is cost-of-
illness study, where only immediate costs of treatment for CHC 
are considered. Whereas, cost-effectiveness study usually needs 
more assumptions and should include clinical outcomes such 
as disease related morbidity or mortality. Thus, cost-of-illness 
studies may provide actual and fundamental data to properly 
conduct cost-effectiveness studies.
Various methodologies in the area of health economy can be 
applied to cost-of-illness studies, each having its own advan-
tages and disadvantages. Furthermore, because of divergence in 
healthcare system and reimbursement policy, it is almost impos-
sible to compare directly the costs incurred by a disease among 
countries. It is also noteworthy that many of the studies esti-
mate only direct costs related to the disease, excluding indirect 
costs such as loss of productive job and transportation fees due 
to absent or incorrect data.3
Cost-estimation studies related to CHC have not been present-
ed in Asian region, even though such countries as Japan and 
Taiwan have a high prevalence of hepatitis C virus (HCV) infec-
tion. In this regard, the article by Ki et al.4 in this issue might be 
relevant, which examined the annual per-patient costs for CHC, 
cirrhosis and hepatocellular carcinoma (HCC) using Korean 
public data. The National Health Insurance (NHI) and Health 
Insurance Review and Assessment (HIRA) claim data between 
2009 and 2013 were the sources for the investigation. Indeed, 
the NHI in South Korea is an unique healthcare system, where 
both costs incurred by inpatient and outpatient care are co-paid 
by government and patient himself, leaving some items such 
as practices, drugs and devices still nonreimbursed. The merit 
of including all the people in Korean national insurance system 
pushed the ex-president of the U.S., Mr. Obama, to revolve U.S. 
healthcare system and to make “Patient Protection and Afford-
able Care Act,” the so called “Obama Care.” In real practice, 
however, Korean NHI system has produced lots of abnormal and 
deviated medical practices due to limited resources, budget and 
non-optimal insurance costs given to the physicians. Anyhow, 
the national universal insurance system enabled the authors to 
perform a comprehensive and uniform cost-of-illness study re-
garding HCV infection, encompassing all the disease states from 
hepatitis to HCC, and all the classes of hospitals from private 
clinic to tertiary university hospital.
In the article of Ki et al.,4 a total of 181,768 patients were 
identified during the study period, and the direct annual per-
patient medical costs, which were calculated by prevalence-
based approach, increased from CHC to cirrhosis, HCC and the 
first year post-liver transplantation; 895, 1,873, 6,945, and 
67,359 USD, respectively. As expected, the direct medical costs 
increased with progression of CHC, because complications of 
cirrhosis such as ascites, variceal bleeding or HCC required 
hospitalization and resource utilization. Increasing direct medi-
cal costs per patient with more advanced CHC-related disease 
were also shown in a previous Korean study, where cost data 
on 445 CHC patients from eight institutions were retrospectively 
reviewed and the monthly direct costs per patient in CHC, com-
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pensated cirrhosis and HCC were estimated to be 77, 98, and 
504 USD, respectively.5 Thus, annual costs per patient in each 
disease state are calculated to be 924, 1,176, and 6,048 USD, 
respectively, which are similar to the estimates in Ki’s study.
The number of patients who received antiviral therapy with 
interferon (or pegylated interferon) and/or ribavirin at least once 
was 25,223 accounting for 13.9% of all the patients between 
2009 and 2013. Interestingly, the costs per patient during the 
study period were 19,743 USD in those who underwent antiviral 
therapy, while the costs in those who did not undergo antiviral 
therapy were 3,126 USD. A substantial proportion (78.5%) of 
costs in patients who received antiviral therapy was incurred 
by drugs including pegylated interferon. However, 37.2% of the 
total costs were incurred by drugs other than antiviral agents 
in those who did not undergo antiviral therapy. What should 
be kept in mind is that cost-of-illness study just estimates im-
mediate costs, and it might be addressed by another kind of cost 
study whether antiviral treatment-related high costs could lower 
overall costs in long-term outcomes.
The authors in their study highlighted low rates of anti-HCV 
treatment uptake (13.9%) over 5-year period. Though these 
figures might underestimate the real rates of treatment because 
some patients had already underwent antiviral therapy before 
the study period, indeed a significant proportion of CHC pa-
tients did not received therapy in the interferon era due to vari-
ous reasons including advanced liver fibrosis, old age and fear 
of adverse events. Additional finding related to antiviral therapy 
is that 1,471 patients received ribavirin monotherapy without 
interferon or pegylated interferon, which is not a recommended 
regimen. There is a need of advertisement and education on the 
proper anti-HCV regimen for physicians in the community uti-
lizing this analysis.
Claim data have its own limitations, resulting in inaccuracy 
and ambiguity. As the authors stated, it may be argued whether 
diagnosis of CHC, cirrhosis and HCC was accurately made with 
ICD-10 codes. Unfortunately, the costs related to management 
of decompensated cirrhosis were not separately estimated due 
to this limitation. Exclusion of non-reimbursed costs from the 
estimation, and the possibility of including costs incurred by co-
morbidities not by CHC itself are also disadvantages.
It has been apparent that healthcare costs increase if CHC-
related diseases are not properly controlled. Overall, the increase 
of costs per person for HCC seems to be greater compared to 
CHC or cirrhosis; from 5,838 to 6,945 USD in HCC versus from 
1,470 to 1,873 USD in cirrhosis versus from 813 to 895 USD in 
CHC (from 2009 to 2013). Therefore, the issue of whether stop-
ping progression of disease with DAAs could decrease health-
care costs needs to be further studied using these data.
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